Katalog der Deutschen Nationalbibliothek

Springe direkt zu:

Katalog (Beta)

Wissensnetz

Person
Person

Person

Daniel Michaeli (1997-)

Arzt

Name

Daniel Michaeli

Zeit

1997- (Lebensdaten)

Ort

Deutschland

Geschlecht

männlich

Akademischer Grad bzw. Titel

Dr. med. (Medizinische Fakultät Mannheim der Universität Heidelberg) (2024)
Dr. rer. oec.

Beruf

Arzt (charakteristischer Beruf)
Wirtschaftswissenschaftler

Variante

Daniel T. Michaeli
Daniel Tobias Michaeli
D. T. Michaeli

Beziehung

Nationales Centrum für Tumorerkrankungen (2023-)
Krebsforschung (Thema)

Weitere Angaben

Department of Medical Oncology, National Center for Tumor Diseases, Heidelberg University Hospital, Heidelberg, Germany.- TUM School of Management, Technical University of Munich, Munich, Germany.- Promotion Bergische Universität Wuppertal 2024 an der Schumpeter School of Economics.- Schwerpunkte: Onkologie, Krebsmedikamente.-

Quelle

https://www.linkedin.com/in/daniel-michaeli/?originalSubdomain=de (Stand: 26.09.2024)

Datensatztyp

Person

GND-Nummer

1277183244

Datensatz-ID

1277183244

Beteiligt an

alle anzeigen

Patient Enrollment per Month (Accrual) in Clinical Trials Leading to the FDA Approval of New Cancer Drugs

Cost-Effectiveness of Lipid-Lowering Therapies for Cardiovascular Prevention

Special FDA designations for drug development: orphan, fast track, accelerated approval, priority review, and breakthrough therapy

Launch and Post-Launch Prices of Injectable Cancer Drugs in the US: Clinical Benefit, Innovation, Epidemiology, and Competition

Gene regulation for inflammation and inflammation resolution differs between umbilical arterial and venous endothelial cells

Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention

Launch sequencing of pharmaceuticals with multiple therapeutic indications: evidence from seven countries

Economics of cancer drugs : development, approval, benefit, trials, innovation, value, price, and competition

Cost-Effectiveness of Icosapent Ethyl, Evolocumab, Alirocumab, Ezetimibe, or Fenofibrate in Combination with Statins Compared to Statin Monotherapy

Value and Price of Multi-indication Cancer Drugs in the USA, Germany, France, England, Canada, Australia, and Scotland

Initial and supplementary indication approval of new targeted cancer drugs by the FDA, EMA, Health Canada, and TGA

Cost-Effectiveness of Bivalent, Quadrivalent, and Nonavalent HPV Vaccination in South Africa

Value drivers of development stage biopharma companies

Valuation and Returns of Drug Development Companies: Lessons for Bioentrepreneurs and Investors

Cost-Effectiveness of Lipid-Lowering Therapies for Cardiovascular Prevention in Germany

Testicular cancer follow-up costs in Germany from 2000 to 2015

Prostate cancer follow-up costs in Germany from 2000 to 2015
Hinweis

Die Betaversion beinhaltet noch nicht alle Funktionen und Informationen des Katalogs des DNB-Portals. Falls Sie Informationen vermissen oder ein Medium bestellen wollen, besuchen Sie bitte die entsprechende Seite im Katalog des DNB-Portals über folgenden Link:

DNB-Portal